Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspen Offers Commitments To Settle EU Price Gouging Claims

Three-Year Investigation Would Close If Company Suggestions Adopted

Executive Summary

After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.

You may also be interested in...



US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce

Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation. 

EU Accepts Aspen Price Commitments

Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.

Aspen Says Reshaping Has Been ‘Painful’ But Is Over Now

Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel